Inivata has announced positive results from the prospective clinical study of its RaDaR liquid biopsy test in patients with head and neck squamous cell carcinoma (HNSCC).

The Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study was conducted in partnership with the Ludwig Maximilian University (LMU) Klinikum, Department of Otorhinolaryngology, Head and Neck Surgery (ORL-HNS) as well as the LMU Munich, Institute of Pathology, Faculty of Medicine.

Blood samples from 17 stage III-IVB, p16-negative HNSCC patients, who received curative-intent primary surgical treatment, were collected for the LIONESS study.

These samples were tested using RaDaR for detecting circulating tumour DNA (ctDNA) for minimal residual disease (MRD) and evidence of the recurrence of the disease pre- and post-surgery.

RaDaR is a multi-tumour, personalised assay, which is designed to track up to 48 tumour-specific variants using a liquid biopsy.

The company stated that all the patients in the study had detectable ctDNA before the surgery.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ctDNA was detected before disease progression in all five patients with clinical recurrence.

The remaining 12 patients had no recurrence and indicated a 100% clinical specificity of the RaDaR assay.

Inivata chief medical officer David Eberhard said: “These data further highlight the clinical utility of our RaDaR assay in the detection of minimal residual disease across tumour types.

“The assay showed exceptionally high sensitivity, detecting ctDNA in every HNSCC patient who went on to recur, which along with its specificity demonstrates the potential of RaDaR to identify HNSCC patients at an increased risk of relapse, enabling earlier intervention and personalised therapy planning.”

Last May, NeoGenomics agreed to exercise an option for the acquisition of Inivata.